Summary of Mirum Pharmaceuticals Conference Call Company Overview - **Company**: Mirum Pharmaceuticals (NasdaqGM:MIRM) - **Event**: 2026 Conference on March 11, 2026 Key Points Financial Guidance and Commercial Strategy - Mirum Pharmaceuticals reiterated its revenue guidance for 2026, projecting between **$630 million and $650 million** [4] - The company is focused on funding R&D programs while maintaining durable trends in commercial performance [4] Upcoming Data Events - Key data events scheduled for Q2 2026 include: - **VISTAS PSC** top-line data, pivotal for potential NDA filing by year-end [4] - **Brelovitug** Phase 2b interim readout from the AZURE-1 study [5] - **EXPAND** top-line readout in Q4 2026 [5] EXPAND Program - The EXPAND program targets ultra-rare cholestasis conditions, with a significant portion of patients expected to be pediatric [7][9] - The potential market for LIVMARLI is projected to reach **at least $1 billion**, with EXPAND contributing approximately one-third of that [9] Geographic Expansion - LIVMARLI is currently available in **low- to mid-30 countries**, with most international sales driven by Alagille syndrome [11] - Opportunities for growth exist in regions like the Middle East and Latin America, where sales have been limited [11] Adult PFIC Market - The adult PFIC market is still in early stages, with increased genetic testing among providers expected to drive growth [12] - The company anticipates continued patient diagnosis and treatment persistence, contributing to long-term growth [13] PSC and PBC Opportunities - Approximately **60%** of diagnosed PSC patients are reported to experience meaningful itch, indicating a significant market for antipruritic therapies [19] - The company plans to conduct market development work to raise awareness of pruritus among healthcare professionals and patients [20] Launch Timeline - Following the release of top-line results, Mirum plans to engage with the FDA for pre-submission interactions, aiming for an NDA filing in the second half of 2026 and potential approval in 2027 [24] - Significant revenue contributions from new products are expected to begin in **2028** [25] Brelovitug Market Development - The company is focused on shifting testing paradigms for hepatitis delta, with a goal to increase diagnosis rates through reflex testing [30][32] - The estimated diagnosed and insured population for delta is around **15,000**, with a full prevalence of approximately **40,000** [33] Competitive Positioning - Brelovitug is positioned as a highly active regimen with a strong safety profile, focusing on endpoints linked to improved patient outcomes [37] - The company anticipates a **$750 million** floor guidance for brelovitug, based on conservative assumptions regarding market penetration [39] Future Growth and Business Development - Mirum remains active in seeking new rare disease programs, maintaining a high bar for potential acquisitions to ensure financial strength [47][48] Additional Insights - The company emphasizes the importance of patient experience and education in driving treatment uptake and market growth [18][21] - Mirum's strategy includes leveraging existing teams and distributor networks to expand market access, particularly in regions with lower GDP [44]

Mirum Pharmaceuticals Conference Call Summary Company Overview - **Company**: Mirum Pharmaceuticals (NasdaqGM:MIRM) - **Focus**: Rare disease medicines, with a strategy centered on developing high-impact therapies for patients with rare diseases [4][5] Financial Performance - **Revenue Guidance**: Expected top line revenue for 2026 is between $630 million and $650 million, reflecting strong performance across three approved medicines [5][29] - **Growth Drivers**: The company anticipates four pivotal readouts over the next 18 months, indicating a pivotal year for growth [5][46] Product Pipeline and Commercial Opportunities LIVMARLI - **Indications**: Approved for Alagille syndrome and PFIC, with ongoing expansion into additional indications through the EXPAND study [8][30] - **Mechanism**: LIVMARLI reduces circulating bile acid levels, significantly alleviating symptoms such as pruritus in patients [8][9] - **Market Dynamics**: Steady growth in Alagille syndrome patient starts; PFIC adoption is dynamic due to increased genetic testing [10][13] - **Sales Growth**: LIVMARLI sales are expected to contribute significantly to the overall revenue, with projections indicating it could become a billion-dollar brand [45][94] Cholbam and CTEXLI - **Sales Performance**: Revenue for Cholbam and CTEXLI has grown to over $160 million, driven by increased awareness and diagnosis efforts [23][24] - **Market Strategy**: Focus on both raising awareness and identifying new patients for these rare conditions [24][26] Brelovitug - **Indication**: Targeting Hepatitis D, a rare and progressive liver disease with significant unmet need [52] - **Clinical Data**: Phase 2 data showed promising results, with a 100% virologic response at 48 weeks [57] - **Enrollment**: Rapid enrollment in registration studies indicates strong interest and potential for success [58] Volixibat - **Indications**: Targeting primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) [78][87] - **Unique Approach**: Using pruritus as a primary endpoint for PSC, which has no approved therapies, represents a novel strategy [78][79] - **Market Potential**: Approximately 30,000 PSC patients in the U.S., with two-thirds experiencing pruritus, indicating a substantial launch population [81][83] Strategic Focus and Future Outlook - **Investment Strategy**: The company aims to balance investments in pipeline development while maintaining a positive cash flow position [98] - **Market Position**: Mirum expects to have a competitive edge in the PSC market due to the lack of approved therapies, allowing for a strong market presence for several years [96][94] - **Long-term Vision**: The company is focused on building value through new medicines and disciplined business development efforts [98][99] Conclusion - Mirum Pharmaceuticals is positioned for significant growth with a robust pipeline and strong commercial performance. The focus on rare diseases and innovative treatment approaches, combined with a solid financial outlook, presents a compelling investment opportunity.

Summary of Mirum Pharmaceuticals FY Conference Call Company Overview - **Company**: Mirum Pharmaceuticals (NasdaqGM:MIRM) - **Focus**: Building a leader in rare diseases by developing and commercializing best-in-class medicines [2][4] Financial Highlights - **2025 Revenue Guidance**: Expected revenues between $630 million and $650 million [2] - **2026 Guidance**: Strong performance anticipated, exceeding consensus estimates [4] Product Pipeline - **Approved Medicines**: Three approved medicines currently available [2] - **Upcoming Trials**: Four pivotal trials expected to unblind over the next 18 months, including: - PSC trial with volixibat in Q2 2026 - Interim analysis for Chenodal with 50 patients - AZURE-1 and AZURE-4 trials for Chenodal in the second half of 2026 - EXPAND trial with LIVMARLI for ultra-rare cholestatic indications [3] Commercial Performance - **LIVMARLI Uptake**: - Strong performance in Alagille syndrome with approximately 50% market penetration and an annual incidence of about 100 patients [4] - Achieving over 80% market share in Alagille [4] - Positive reception in PFIC, capturing at least 50% of treatment-naive patients [4][5] - **Ex-US Market**: Good visibility in major Western European countries, with growth expected in Alagille and PFIC [7] Expansion Opportunities - **EXPAND Study**: Initiated due to high demand from compassionate use requests; includes various ultra-rare indications [8] - **Market Potential**: Estimated peak sales for LIVMARLI could exceed $1 billion, with a third of sales from Alagille, PFIC, and the EXPAND population [10] Intellectual Property - **Patent Expiration**: Expected to extend to 2040 for dosing patents and 2043 for tablet patents [13] Volixibat Development - **Target Population**: Aimed at adults with PSC and PBC, with expectations for a clinically meaningful difference of at least 1.75 placebo-adjusted [15][20] - **Interim Results**: Positive interim results for PBC with significant pruritus benefits observed [21] Strategic Acquisitions - **Bluejay Therapeutics**: Acquired to enhance the hepatitis delta program, with a potential patient population of at least 15,000 diagnosed patients [31][33] Competitive Landscape - **Hepatitis Delta Treatment**: Brelovitug expected to have advantages in convenience and tolerability compared to competitors [35] - **Market Dynamics**: Anticipated increase in diagnosis rates with the introduction of new therapies [33] Future Outlook - **Regulatory Submissions**: NDA filing expected in the second half of 2026 following positive trial results [20] - **Commercial Strategy**: Plans to expand marketing efforts for volixibat and other therapies, focusing on community gastroenterologists and hepatologists [38] Conclusion - **Growth Potential**: Mirum Pharmaceuticals is positioned for significant growth in the rare disease market, with a robust pipeline and strategic acquisitions enhancing its portfolio [41]

Financial Data and Key Metrics Changes - In 2025, the company achieved $521 million in net product sales, a 55% increase from $336 million in 2024 [5][14] - The fourth quarter of 2025 saw net product sales of $149 million, compared to $99 million in the same quarter of the previous year [14] - The company ended 2025 with $391 million in cash equivalents, up from $293 million at the end of 2024 [15] Business Line Data and Key Metrics Changes - LIVMARLI net product sales were $245 million in the U.S. and $115 million internationally, with bile acid medicines contributing an additional $161 million [5] - The commercial cash contribution margin in 2025 was approximately 55%, a significant increase from the prior year [15] Market Data and Key Metrics Changes - The company expects net product sales for 2026 to be between $630 million and $650 million, indicating continued growth [6] - The company anticipates a return to positive cash flow in 2027, following increased R&D expenses in 2026 [16] Company Strategy and Development Direction - The company is focused on advancing its pipeline with multiple clinical and regulatory milestones, including the approval of Ctexli for CTX and a tablet formulation of LIVMARLI [6][7] - The addition of the phase III brelovitug program for chronic hepatitis delta virus aligns with the company's strategy to address significant unmet needs in rare diseases [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026, highlighting a strong commercial business and a robust pipeline with four potentially pivotal readouts expected in the next 18 months [17] - The company is committed to disciplined execution and delivering impactful medicines for patients with rare diseases [9][17] Other Important Information - The company completed two private placements concurrent with the closing of the Bluejay acquisition, generating gross proceeds of $268.5 million [15] - The company is on track to report top-line data from the volixibat VISTA study in PSC in the second quarter of 2026 [10][11] Q&A Session Summary Question: Volixibat pricing strategy - Management indicated that pricing considerations for volixibat will be based on data closer to launch, noting its unique positioning due to the lack of approved medicines for PSC [19][20] Question: Risk factors in PSC trial - Management acknowledged the episodic nature of pruritus in PSC patients and emphasized the study design's focus on enrolling patients with persistent pruritus to limit variability [25][28] Question: Similarities between VISTA and VANTAGE study designs - Management highlighted commonalities in studying cholestatic pruritus and confirmed that patients with moderate to severe pruritus will be selected for both studies [35][36] Question: FDA interactions regarding safety database for volixibat - Management confirmed that the current VISTA study has a sufficient safety database and plans to interact with the FDA regarding the submission plan after top-line data [40] Question: Market for hepatitis delta virus (HDV) - Management noted the evolving landscape for HDV treatments and expressed optimism about brelovitug's potential as a best-in-class option [70][71] Question: R&D spending increase for HDV studies - Management anticipates a $150 million increase in R&D spending related to the brelovitug program, with significant investments in CMC [72]

Financial Data and Key Metrics Changes - In 2025, the company achieved $521 million in net product sales, a 55% increase from $336 million in 2024, exceeding the upper end of guidance [5][14] - The total net product sales for Q4 2025 was $149 million, compared to $99 million in Q4 2024 [14] - The commercial cash contribution margin in 2025 was approximately 55%, significantly up from the previous year [15] Business Line Data and Key Metrics Changes - LIVMARLI net product sales were $245 million in the U.S. and $115 million internationally, with bile acid medicines contributing an additional $161 million [5] - The company expects net product sales for 2026 to be between $630 million and $650 million, indicating continued growth [6] Market Data and Key Metrics Changes - The company is seeing strong demand in international markets, particularly for LIVMARLI and its bile acid medicines [5] - The integration of the Bluejay acquisition has progressed smoothly, enhancing the company's operational capabilities [8] Company Strategy and Development Direction - The company is focused on advancing its pipeline with significant clinical and regulatory milestones, including the approval of CTEXLI and the enrollment completion of the VISTAS study for volixibat [6][7] - The addition of the phase III brelovitug program for chronic hepatitis delta virus aligns with the company's strategy to address serious rare diseases [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026, highlighting a pivotal year with multiple potential registrational readouts expected [6][17] - The company anticipates a return to positive cash flow in 2027, supported by disciplined spending and a strong balance sheet [16] Other Important Information - The company ended 2025 with $391 million in cash equivalents, up from $293 million at the end of 2024 [15] - R&D expenses are expected to increase in 2026 due to investments in the brelovitug clinical program and preparations for BLA submission [16] Q&A Session Summary Question: Regarding volixibat's commercial opportunity and pricing strategy - Management indicated that pricing decisions will be made closer to launch, considering the unique positioning of volixibat in the market [19][20] Question: Concerns about pruritus variability in PSC patients - Management acknowledged the episodic nature of pruritus in PSC and emphasized careful patient selection and monitoring in the study design [25][28] Question: Differences between VISTAS and VANTAGE study designs - Management highlighted the commonality in studying cholestatic pruritus while noting the differences in disease etiology between PSC and PBC [33][35] Question: FDA interactions regarding safety database requirements for volixibat - Management confirmed that the current VISTAS study has a sufficient safety database and plans to interact with the FDA post-top-line data [40] Question: Market expectations for HDV and R&D spending - Management discussed the evolving treatment landscape for HDV and anticipated a $150 million increase in R&D spend related to brelovitug [70][72]

Financial Data and Key Metrics Changes - In 2025, the company achieved $521 million in net product sales, a 55% increase from $336 million in 2024, exceeding guidance [4][13] - The total operating expense for 2025 was $543 million, which included R&D expenses of $186 million and SG&A expenses of $257 million [13][14] - The commercial cash contribution margin improved to approximately 55% in 2025, up from the previous year [14] Business Line Data and Key Metrics Changes - LIVMARLI net product sales were $245 million in the U.S. and $115 million internationally, contributing significantly to the overall sales [4] - The bile acid medicines contributed an additional $161 million to the total sales [4] Market Data and Key Metrics Changes - The company expects net product sales for 2026 to be between $630 million and $650 million, indicating continued growth [5] - The company is entering 2026 with a strong pipeline, including four potentially registrational clinical readouts expected over the next 18 months [8] Company Strategy and Development Direction - The company is focused on disciplined execution and growth, with a strong emphasis on advancing its pipeline through clinical and regulatory milestones [5][6] - The addition of brelovitug for chronic hepatitis delta virus is seen as a strategic fit, enhancing the company's portfolio and potential revenue [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for 2026, highlighting the strong performance of the commercial business and the robust pipeline [16] - The company anticipates a return to positive cash flow in 2027, supported by disciplined spending and a strong balance sheet [15] Other Important Information - The company completed two private placements generating gross proceeds of $268.5 million, which will support the acquisition and operational needs [14] - The company has received Fast Track designation from the FDA for MRM-3379 in Fragile X syndrome, indicating its potential to address significant unmet needs [12] Q&A Session Summary Question: Pricing strategy for volixibat - Management indicated that pricing considerations for volixibat will be based on data and market positioning, noting the unique opportunity in the absence of approved therapies for PSC [18][19] Question: Variability in pruritus in PSC patients - Management acknowledged the episodic nature of pruritus in PSC and emphasized the study design's focus on enrolling patients with persistent pruritus to ensure relevant data [23][27] Question: Similarities and differences in study designs for PSC - Management highlighted the commonality in studying cholestatic pruritus across different conditions, with a focus on ensuring that patients with moderate to severe pruritus are enrolled [32][34] Question: FDA interactions regarding safety database for volixibat - Management confirmed that the current study has a sufficient safety database and plans to interact with the FDA regarding submission plans after top-line data is available [38] Question: Market potential for HDV - Management discussed the evolving landscape for HDV treatments and the potential for brelovitug to set a new standard in response rates and safety profiles [68] Question: R&D spending increase for HDV studies - Management anticipates a $150 million increase in R&D spending related to brelovitug, with significant investments in manufacturing and clinical studies [70]

Core Insights - Saira Ramasastry, a director at Mirum Pharmaceuticals, executed the exercise of 5,000 stock options and sold the resulting shares for a total transaction value of $400,000 on December 22 [2][7]. Transaction Summary - The transaction involved the direct sale of 5,000 shares, with a total value of $400,000, based on a weighted average purchase price of $80.00 per share [3]. - Post-transaction, Ramasastry holds no direct common shares, as the entire transaction accounted for 100% of her direct holdings [8]. Company Overview - Mirum Pharmaceuticals reported a revenue of $471.79 million and a net income of -$41.42 million for the trailing twelve months (TTM) [5]. - The company's stock price increased by 90.71% over the past year, calculated using December 22 as the reference date [5]. Company Snapshot - Mirum specializes in developing therapies for rare and orphan liver diseases, with its lead product being LIVMARLI and additional candidates like Volixibat in its pipeline [6]. Operational Performance - Preliminary results for 2025 indicate net product sales of approximately $520 million, exceeding guidance, with forecasts of $630 million to $650 million in global net product sales for 2026 [11]. - The company ended 2025 with an estimated $392 million in cash and investments and achieved positive operating cash flow, allowing for pipeline expansion and the proposed acquisition of Bluejay Therapeutics [11].

Core Insights - Mirum is a biopharmaceutical company focused on therapies for rare and orphan diseases, particularly liver disorders, leveraging its drug development expertise to meet significant unmet medical needs [1] - The company has seen a substantial increase in its stock price, with shares priced at $79.26, reflecting an 89% increase over the past year, significantly outperforming the S&P 500's 15% rise [2] Financial Performance - Mirum reported third-quarter revenue of $133 million, representing a 47% increase year-over-year, and raised its full-year revenue guidance to between $500 million and $510 million, driven by strong sales of LIVMARLI and expanding bile acid medicine revenue [6] - The company's cash and investments reached $378 million by the end of the quarter, providing financial flexibility to support multiple pipeline developments without immediate dilution concerns [6] Shareholder Activity - Eventide Asset Management sold 114,922 shares of Mirum, reducing its stake but increasing the net position value by approximately $50.70 million due to the stock price surge [3][4] - Despite the sale, Mirum became the second-largest equity holding in Eventide's portfolio, indicating a strategic decision to maintain a significant position in a company with strong growth potential [5] Market Position - Mirum's focus on rare disease markets provides a competitive advantage by targeting high-value, underserved patient populations, which is critical for driving growth through proprietary product commercialization [1]

Core Insights - Mirum Pharmaceuticals Inc. is identified as a high short interest stock with significant investment potential, particularly following the acquisition of Bluejay and the addition of the drug brelovitug to its pipeline [1][3] - The company reported a strong Q3 2025 earnings performance, with quarterly revenue reaching $133 million, reflecting a ~50% year-over-year increase and a positive net income of ~$3 million [2][3] Financial Performance - Q3 2025 revenue totaled $133 million, marking a ~50% increase year-over-year [2] - The primary revenue driver was product sales, with LIVMARLI net product sales at $92 million, including $64 million from the US and $28 million from international sales [2] - Additional sales from Bile Acid Medicines contributed $41 million to net product sales [2] Strategic Developments - Morgan Stanley raised the price target for Mirum Pharmaceuticals to $95 from $81, citing the strategic significance of the Bluejay acquisition and the promising potential of brelovitug in treating hepatitis delta virus [1][3] - The acquisition is expected to enhance the company's rare liver disease pipeline and create valuable synergies [1] Market Challenges - Despite strong performance, the company faces commercial variability, particularly with international sales of LIVMARLI due to large periodic orders from distributors [3] - Management anticipates a sequential decline in revenue for Q4 and does not expect additional sales to its partner, Takeda, in Japan during that quarter [3] - There is ongoing uncertainty regarding the pricing strategy for the investigational drug volixibat as the company analyzes market dynamics [3]

Financial Data and Key Metrics Changes - The company reported third quarter revenue of $133 million, representing a nearly 50% year-over-year increase [5][16] - Total net product revenue increased by 47% compared to the prior year, reflecting growth across all commercial medicines [16] - The company achieved positive net income for the first time, generating approximately $3 million in net income [7][17] Business Line Data and Key Metrics Changes - LIVMARLI net product sales totaled $92 million for the quarter, with $64 million in the U.S. and $28 million internationally [9][10] - The bioacquired portfolio, including CHOLBAM and CHENODAL, generated $41 million in net product sales this quarter [10] - The company expects to land in the upper end of its prior full year 2025 guidance range, with projected revenues of $500-$510 million [10] Market Data and Key Metrics Changes - Demand for LIVMARLI in the U.S. remains healthy, particularly in Alagille syndrome and PFIC, with continued growth expected [9] - Internationally, LIVMARLI demand continues to grow, supported by expanding reimbursement and launches in new geographies [10] - The first full quarter of commercialization for Takeda in Japan showed in-market adoption dynamics consistent with LIVMARLI's U.S. launch [10] Company Strategy and Development Direction - The company aims to create and deliver life-changing medicines to patients, focusing on rare diseases [5] - There is a strong emphasis on expanding the commercial portfolio and advancing the clinical pipeline, with three potentially pivotal readouts expected over the next 18 months [6][7] - The company is optimistic about the peak revenue potential for LIVMARLI, Volixibat, and MRM-3379, each exceeding $1 billion [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue executing with focus and consistency, highlighting the importance of patient-centric approaches [5][18] - The company remains well-funded and financially independent, providing resources for expansion and growth [17] - Management noted that while quarterly GAAP profitability is a milestone, it is not yet a consistent expectation as the company continues to invest in growth [17] Other Important Information - The company completed enrollment in the phase 2b VISTAS study in primary sclerosing cholangitis (PSC) and expects to announce top-line data in the second quarter of 2026 [12] - The company is actively monitoring the competitive landscape, particularly regarding pricing strategies for Volixibat [28][68] Q&A Session Summary Question: Key drivers of LIVMARLI's performance in 2026 and guidance for Q4 - Management expects continued growth from the PFIC launch and other existing dynamics, with guidance for Q4 reflecting variability in international sales [20][22] Question: Trends in adoption of LIVMARLI's solid tablet formulation - The solid tablet formulation has seen encouraging uptake, with a substantial proportion of eligible patients switching from the liquid form [26][27] Question: Expectations for Paragraph IV filers and IP portfolio confidence - Management expressed confidence in the overall IP position, particularly regarding method patents for LIVMARLI [32][34] Question: Insights on Fragile X study endpoints and safety risks in PSC - Management is optimistic about the endpoint strategy for Fragile X and noted no significant safety issues in the PSC study [40][42] Question: Impact of government shutdown on genetic screening programs - No impact has been observed on genetic screening programs or business interactions due to the government shutdown [56] Question: Pace of new PFIC adds and business development strategy - The pace of new PFIC adds remains healthy, with ongoing educational efforts to increase awareness among providers [60][63]